With the list now containing a total of 19 relevant preclinical studies, EPHA2 is, undoubtedly, the most studied EPH/ephrin target in BC treatment, the targeting of which mainly results in cell death induction, tumor growth inhibition, as well as anticancer immune system response. This evidence concerns the gene EPHA1 and breast cancer.